Inflammation control: lowered pro-inflammatory factors (IL-6, IL-1β, and TNF-α) while increasing anti-inflammatory factors (IFN-β, IL-10, and IL-4).<h4>Conclusions</h4>PNID may serve as a promising complementary therapy for PD. This evidence concerns the gene IL1B and Parkinson disease.